Ya disponibles los comunicaciones GETECCU que serán presentadas en la ECCO 2022 divididas por tipo de comunicación.

Oral comunication:

  • DOP04: Inflammatory Bowel Disease (IBD) and Solid Organ Transplantation. Natural history of pre-existing and de novo IBD patients. (EITOS study of GETECCU). Iria Bastón
  • DOP78: Comparative study of the effectiveness of vedolizumab versus ustekinumab after anti-TNF failure (VERSUS-CD). Mª José García

Poster:

  • P118: Inflammatory Bowel Disease Unclassified and Ulcerative Colitis: different outcomes? Multicenter case-control study (Spanish ENEIDA registry). María González Vivó
  • P290: Therapeutic requirements in patients with Ulcerative Proctitis. Is it necessary immunosuppressive therapy in these patients?. Rocío Ferreiro
  • P289: Evaluation of the safety and effectiveness of direct-acting antiviral drugs in the treatment of hepatitis C in patients with inflammatory bowel disease: National multicenter study (ENEIDA registry). MIC project. Alberto Martín Cardona
  • P349: Safety of Inflammatory Bowel Disease treatments in patients with Solid Organ Transplantation (EITOS study of GETECCU). Iria Bastón –
  • P371: The addition of intravenous, high dose, bolus of methyl-prednisolone increases the early clinical response to oral corticosteroids in moderately active ulcerative colitis. Preliminary results of a prospective, controlled, multicentre, randomised, open-label study. Eugeni Domènech
  • P410: safety of biological drugs for inflammatory bowel disease in elderly patients. Cristina Suárez (Grupo Joven)
  • P481: profile of elderly patients in which biological drugs are used for the treatment of inflammatory bowel disease. Cristina Suárez (Grupo Joven)
  • P523: effectiveness of biological treatments for inflammatory bowel disease in the elderly patients. Cristina Suárez (Grupo Joven)
  • P545: Safety of ustekinumab in pregnant patients with inflammatory bowel disease and in their offspring: results from the DUMBO registry of GETECCU. María Chaparro
  • P550: Management of immunomodulators and biologic agents in pregnant patients with inflammatory bowel: results from the DUMBO registry of GETECCU. María Chaparro
  • P654: Clinical outcomes in familial versus sporadic inflammatory bowel disease diagnosed in the era of biological therapies. Prospective data from the ENEIDA registry. Carlos González Muñoza